Search


Ovid Therapeutics' new CEO Meg Alexander walks us through the company's lead programs in neurology
She discusses the GABA-aminotransferase inhibitor, OV329, and KCC2 programs.
Feb 2


Ovid's Jeremy Levin on advances in CNS, soticlestat, ROCK2, Washington and more
Jeremy Levin walks us through the science of Ovid's CNS-focused pipeline, gives his take on the health of the biotech.
Jan 22, 2024






.png)
